{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T14:26:45Z","timestamp":1772720805679,"version":"3.50.1"},"reference-count":19,"publisher":"Georg Thieme Verlag KG","issue":"09","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rofo"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:p>\n            Purpose\u2002To analyze tumor response, survival and safety in patients with non-resectable hepatocellular carcinoma (HCC) treated with transarterial hepatic chemoembolization using degradable starch microspheres (DSM-TACE) combined with doxorubicin who had no local interventional or systemic therapy alternative according to an interdisciplinary conference.<\/jats:p><jats:p>\n            Materials and Methods\u2002In this retrospective study, 28 patients (23\u00a0male, 5 female, median age 67 years) with unresectable HCC, serum bilirubin levels &lt;\u200a3\u200amg\/dl and contraindications to Sorafenib, RFA, SIRT or cTACE were included. DSM-TACE was performed using Embocept\u00ae S (15\u200aml) and doxorubicin (50\u200amg\/25\u200aml) three times every 4\u20136 weeks. Patients were initially staged using the Barcelona Clinic Liver Cancer System (BCLC). Basic liver function was evaluated with the MELD-score. Tumor response was assessed using the modified Response Evaluation Criteria in Solid Tumors (mRECIST).<\/jats:p><jats:p>\n            Results\u2002DSM-TACE could be technically successfully performed in all 28 patients. At control imaging after three treatments, the overall rates of complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD) were 14.3\u200a%, 25\u200a%, 39.3\u200a% and 21.4\u200a%, respectively, according to mRECIST. With regard to BCLC stages, the results were as follows (CR, PR, PD): BCLC A (n\u200a=\u200a8): 7.1\u200a%, 7.1\u200a%, 10.7\u200a%, 1.2\u200a%; BCLC B (n\u200a=\u200a12): 0\u200a%, 10.7\u200a%, 17.9\u200a%, 14.3\u200a%; BCLC C (n\u200a=\u200a5): 0\u200a%, 3.6\u200a%, 10.7\u200a%, 3.6\u200a%; BCLC D (n\u200a=\u200a3): 3.6\u200a%, 3.6\u200a%, 0\u200a%, 3.6\u200a%. According to this, DSM-TACE showed an overall good median survival of 682 days, although the patients\u2019 survival was strictly dependent on BCLC stage.<\/jats:p><jats:p>\n            Conclusion\u2002DSM-TACE is a safe and promising treatment alternative for patients with unresectable HCC who are ineligible for other loco-regional therapies.<\/jats:p><jats:p>\n            Key Points:\u2002<\/jats:p><jats:p>\n            Citation Format\n          <\/jats:p>","DOI":"10.1055\/a-1111-9955","type":"journal-article","created":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T23:59:37Z","timestamp":1583366377000},"page":"862-869","source":"Crossref","is-referenced-by-count":12,"title":["DSM-TACE of HCC: Evaluation of Tumor Response in Patients Ineligible for Other Systemic or Loco-Regional Therapies"],"prefix":"10.1055","volume":"192","author":[{"given":"Johannes","family":"Haubold","sequence":"additional","affiliation":[{"name":"Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus P.","family":"Reinboldt","sequence":"additional","affiliation":[{"name":"Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Wetter","sequence":"additional","affiliation":[{"name":"Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes Maximilian","family":"Ludwig","sequence":"additional","affiliation":[{"name":"Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Lange","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Hospital Essen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heiner","family":"Wedemeyer","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Hospital Essen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clemens","family":"Schotten","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Hospital Essen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lale","family":"Umutlu","sequence":"additional","affiliation":[{"name":"Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Theysohn","sequence":"additional","affiliation":[{"name":"Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2020,3,4]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/ajg.2014.11","article-title":"Changing hepatocellular carcinoma incidence and liver cancer mortality rates in the United States","volume":"109","author":"S F Altekruse","year":"2014","journal-title":"Am. J. Gastroenterol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.bpg.2014.08.007","article-title":"Hepatocellular carcinoma epidemiology","volume":"28","author":"C Bosetti","year":"2014","journal-title":"Best Pract. Res. Clin. Gastroenterol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.jhep.2011.12.001","article-title":"EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma","volume":"56","author":"European Association For The Study Of The Liver, European Organisation For Research And Treatment Of Cancer","year":"2012","journal-title":"J. Hepatol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"J M Llovet","year":"2008","journal-title":"N. Engl. J. Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"A-L Cheng","year":"2009","journal-title":"Lancet Oncol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1136\/gutjnl-2017-315068","article-title":"Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma","volume":"67","author":"A Gerbes","year":"2018","journal-title":"Gut"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin","volume":"30","author":"R Lencioni","year":"2010","journal-title":"Liver Dis"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"S189","DOI":"10.1016\/j.jvir.2009.04.035","article-title":"Society of Interventional Radiology clinical practice guidelines","volume":"20","author":"J F Cardella","year":"2009","journal-title":"J. Vasc. Interv. Radiol. JVIR"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.24199","article-title":"Management of hepatocellular carcinoma: an update","volume":"53","author":"J Bruix","year":"2011","journal-title":"Hepatol. Baltim. Md"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1051-0443(07)61403-1","article-title":"Classifying complications of interventional procedures: a survey of practicing radiologists","volume":"12","author":"C J Leoni","year":"2001","journal-title":"J. Vasc. Interv. Radiol. JVIR"},{"key":"ref11","first-page":"2872","article-title":"Transarterial chemoembolization with degradable starch microspheres (DSM-TACE): an alternative option for advanced HCC patients? Preliminary results","volume":"20","author":"R Iezzi","year":"2016","journal-title":"Eur. Rev. Med. Pharmacol. Sci"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.4254\/wjh.v7.i12.1694","article-title":"Downstaging disease in patients with hepatocellular carcinoma outside up-to-seven criteria: Strategies using degradable starch microspheres transcatheter arterial chemo-embolization","volume":"7","author":"A Orlacchio","year":"2015","journal-title":"World J. Hepatol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3233\/CH-2012-1590","article-title":"Degradable starch microspheres transarterial chemoembolisation (DSM-TACE) of HCC: Dynamic Contrast-Enhanced Ultrasonography (DCE-US) based evaluation of therapeutic efficacy using a novel perfusion software","volume":"52","author":"P Wiggermann","year":"2012","journal-title":"Clin. Hemorheol. Microcirc"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3233\/CH-2012-1555","article-title":"Dynamic evaluation and quantification of microvascularization during degradable starch microspheres transarterial Chemoembolisation (DSM-TACE) of HCC lesions using contrast enhanced ultrasound (CEUS): a feasibility study","volume":"53","author":"P Wiggermann","year":"2013","journal-title":"Clin. Hemorheol. Microcirc"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"8853","DOI":"10.3748\/wjg.v22.i40.8853","article-title":"Transarterial chemoembolization with drug-eluting beads in hepatocellular carcinoma","volume":"22","author":"H C Nam","year":"2016","journal-title":"World J. Gastroenterol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.clinre.2016.05.013","article-title":"Evaluation of drug-eluting beads versus conventional transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma: A systematic review and meta-analysis","volume":"41","author":"P Chen","year":"2017","journal-title":"Clin. Res. Hepatol. Gastroenterol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/hep.20933","article-title":"Management of hepatocellular carcinoma","volume":"42","author":"J Bruix","year":"2005","journal-title":"Hepatol. Baltim. Md"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.jhep.2016.01.012","article-title":"Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial","volume":"64","author":"R Lencioni","year":"2016","journal-title":"J.\u00a0Hepatol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1007\/s00270-016-1512-1","article-title":"Pharmacokinetics and Histopathological Findings of Chemoembolization Using Cisplatin Powder Mixed with Degradable Starch Microspheres in a Rabbit Liver Tumor Model","volume":"40","author":"T Sato","year":"2017","journal-title":"Cardiovasc. Intervent. Radiol"}],"container-title":["R\u00f6Fo - Fortschritte auf dem Gebiet der R\u00f6ntgenstrahlen und der bildgebenden Verfahren"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1111-9955.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T23:32:17Z","timestamp":1597966337000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1111-9955"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,4]]},"references-count":19,"journal-issue":{"issue":"09","published-online":{"date-parts":[[2020,8,20]]},"published-print":{"date-parts":[[2020,9]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1111-9955","relation":{},"ISSN":["1438-9029","1438-9010"],"issn-type":[{"value":"1438-9029","type":"print"},{"value":"1438-9010","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,4]]}}}